Methylprednisolone in Pregnancy: Trimester-Specific Safety and Monitoring
Methylprednisolone (intermediate-acting glucocorticoid) crosses placenta but is partially inactivated by placental 11β-HSD2 (converts to inactive 20-methyl derivative). Fetal exposure ~10–20% maternal levels.
Trimester-Specific Considerations
| Trimester | Risk/Benefit | Guidance |
|---|---|---|
| 1st (Organogenesis) | Animal data: cleft palate at high doses. Human data: no consistent major malformation signal at therapeutic doses. Slight ↑ oral clefts in some cohorts (confounded by indication). | Avoid if possible. If needed for severe disease (asthma flare, SLE, MS relapse): lowest effective dose, shortest duration. Counsel on theoretical risk. |
| 2nd/3rd | Fetal organogenesis complete. Risks: growth restriction, adrenal suppression, neonatal hypoglycemia with prolonged high-dose. | Safer for indicated conditions (asthma, IBD, autoimmune). Monitor fetal growth (US q4wks if >2 wks use). Stress-dose at delivery if prolonged use. |
